PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B

Vector-gene combination developed at St. Jude Children's Research Hospital and UCL is central to latest clinical trial of gene therapy as a possible tool to provide long-term relief from disabling bleeds

2010-12-07
(Press-News.org) Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

This trial was designed primarily as a safety test, with low and intermediate doses of the vector expected to produce little detectable Factor IX. The Factor IX protein helps the blood form clots. Individual with hemophilia B lack adequate levels of this clotting factor. The first participant in the open-label Phase I/II trial had an unexpectedly high level of Factor IX expression after receiving the lowest dose of the vector being tested in this study. Levels of the Factor IX protein rose from less than 1 percent to 2 percent of normal after the experimental vector was infused into the patient.

The patient's Factor IX production remains elevated more than nine months later. Since the infusion the patient has also not suffered any spontaneous joint bleeds or needed prophylactic treatment.

Study data was presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) by Amit Nathwani, M.D., Ph.D., UCL Department of Hematology, and National Health Service Blood and Transplant, UK, the study's first author. Andrew Davidoff, M.D., chair of the St. Jude Department of Surgery, is the senior author.

Work on the vector began more than 10 years ago in the St. Jude laboratory of Arthur Nienhuis, M.D., member of the Department of Hematology and a study co-author. The collaboration continued after Nathwani returned to London.

The trial vector was made by packaging a codon-optimized version of the Factor IX gene into a member of the adeno-associated virus (AAV) family known as AAV8. AAV8 was picked because the incidence of natural infection with AAV8 is low and, like other AAVs, targets liver cells but does not integrate into the patient's DNA. Participants received no immune suppressing drugs prior to infusion of the experimental vector.

Results so far suggest the experimental vector does not trigger the T-cell mediated immune response seen in a previous hemophilia B gene therapy trial.

The third and highest dose of the novel gene-vector combination is scheduled to be infused into the fifth and sixth study participants by mid-January. Investigators will then decide whether to expand the trial to include four more adults with severe hemophilia B. Study participants were all recruited at UCL/Royal Free Hospital through the efforts of co-author Edward G.D. Tuddenham, M.D.

Davidoff and Nathwani noted that hemophilia B has been the main focus of gene therapy efforts for disorders affecting the liver because the threshold required for therapeutic effect is modest. In patients with severe hemophilia B whose baseline level of Factor IX is less than 1 percent, generating expression of just 5 percent has the potential to dramatically affect their quality of life, reducing disabling and painful episodes of bleeding and eliminating the need for costly infusions of the protein.

Factor IX is needed for normal clot formation. A mutation in the gene that carries instructions for assembling the protein leaves about 1 in 30,000 individuals at risk for disabling episodes of internal and external bleeding. The gene is carried on the X chromosome, and the disorder is almost exclusively a male disease.

The trial vector was made at the Children's Good Manufacturing Practices (GMP), LLC, facility, on the St. Jude campus. The GMP operates under government-approved manufacturing guidelines and produces the highly specialized medicines and vaccines that pharmaceutical companies are reluctant to pursue.

INFORMATION:

The other authors are Cecilia Rosales and Jenny McIntosh (both of UCL); Anne Riddell (KD Haemophilia Centre and Thrombosis Unit); Pradip Rustagi, Bertil Glader and Mark Kay (all of Stanford University); Katherine High and Federico Mingozzi (both of The Children's Hospital of Philadelphia) and James Allay, Susan Sleep, John Gray, Ulrike Reiss and the late John Coleman (all of St. Jude).

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other catastrophic diseases. Ranked the No. 1 pediatric cancer hospital by Parents magazine and the No. 1 children's cancer hospital by U.S. News & World Report, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has treated children from all 50 states and from around the world, serving as a trusted resource for physicians and researchers. St. Jude has developed research protocols that helped push overall survival rates for childhood cancer from less than 20 percent when the hospital opened to almost 80 percent today. St. Jude is the national coordinating center for the Pediatric Brain Tumor Consortium and the Childhood Cancer Survivor Study. In addition to pediatric cancer research, St. Jude is also a leader in sickle cell disease research and is a globally prominent research center for influenza.

Founded in 1962 by the late entertainer Danny Thomas, St. Jude freely shares its discoveries with scientific and medical communities around the world, publishing more research articles than any other pediatric cancer research center in the United States. St. Jude treats more than 5,700 patients each year and is the only pediatric cancer research center where families never pay for treatment not covered by insurance. St. Jude is financially supported by thousands of individual donors, organizations and corporations without which the hospital's work would not be possible. In 2010, St. Jude was ranked the most trusted charity in the nation in a public survey conducted by Harris Interactive, a highly respected international polling and research firm. For more information, go to www.stjude.org.

UCL (University College London)

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. UCL is among the world's top universities, as reflected by performance in a range of international rankings and tables. Alumni include Marie Stopes, Jonathan Dimbleby, Lord Woolf, Alexander Graham Bell and members of the band Coldplay. UCL currently has over 13,000 undergraduates and 9,000 postgraduate students. Its annual income is over £ 700 million. www.ucl.ac.uk

END



ELSE PRESS RELEASES FROM THIS DATE:

People with severe mental illness 12 times more likely to commit suicide

2010-12-07
People with psychotic disorders, such as schizophrenia or bipolar disorder, are 12 times more likely to commit suicide than average, according to research released today by King's Health Partners. The research found that the rate of suicide was highest in the first year following diagnosis (12 times national average) and that high risk persisted – remaining four times greater than the general population ten years after diagnosis, a time when there may be less intense clinical monitoring of risk. Neither the risk of suicide nor the long-term risk of suicide, as compared ...

Profiling based on mobile, online behavior: A privacy issue

2010-12-07
CORVALLIS, Ore. – It's illegal for businesses and law enforcement to profile a person based on their race, gender, or ethnicity, yet millions of Americans are being profiled every day based on their online consumer behavior and demographics. Known as consumer profiling for behavioral advertising purposes, this type of profiling is largely unregulated. The result, according to two recent articles in the journal of Computer Law & Security Review, is that consumers have less privacy and are being targeted by advertisers using increasingly sophisticated measures, which ...

The taster in your water line

The taster in your water line
2010-12-07
It is supposed to be cool, colorless, tasteless and odorless. It may not have any pathogens or impair your health. This is the reason why drinking water is put to a whole series of screenings at regular intervals. Now, the AquaBioTox project will be added to create a system for constant real-time drinking water monitoring. At present, the tests required by the German Drinking Water Ordinance are limited to random samples that often only provide findings after hours and are always attuned to specific substances. In contrast, the heart of the AquaBioTox system is a bio-sensor ...

Scientists find gene linked to congenital heart defect

Scientists find gene linked to congenital heart defect
2010-12-07
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect. Princeton researchers focused on identifying and studying the gene in zebrafish embryos, and the team's work expanded to include collaborations with other groups studying the genetics of mice and people. "This work really showcases the use of collaborative science and multiple model systems to better understand human disease," ...

Parkinson's drug could treat restless leg syndrome

Parkinsons drug could treat restless leg syndrome
2010-12-07
AUGUSTA, Ga. – A drug prescribed for Parkinson's disease may also treat restless leg syndrome without the adverse side effects of current therapies, Medical College of Georgia researchers say. Rasagaline works by prolonging the effect of dopamine, a chemical that transmits signals between nerve cells in the brain. The cause of RLS is unknown, but research suggests a dopamine imbalance. Parkinson's is caused by a dopamine insufficiency. "The hope is that Rasagaline, because it prolongs the effect of existing dopamine, instead of producing more, will not come with adverse ...

Mayo Clinic finds long-term prognosis is excellent for most children with seizures

2010-12-07
ROCHESTER, Minn. -- Mayo Clinic researchers studied more than 200 children with epilepsy and found that even if the cause of focal-onset seizures cannot be identified and they do not fit into a known epilepsy syndrome, long-term prognosis is still excellent. This study was presented at the American Epilepsy Society's (http://www.aesnet.org/) annual meeting in San Antonio on Dec. 4. Epilepsy (http://www.mayoclinic.org/epilepsy/) is a disorder characterized by the occurrence of two or more seizures. It affects almost 3 million Americans, and approximately 45,000 children ...

Scientists announce discovery of first horned dinosaur from South Korea

2010-12-07
Cleveland - Scientists from South Korea, the United States and Japan analyzed fossil evidence found in South Korea and published research describing a new horned dinosaur. The newly identified genus, Koreaceratops hwaseongensis, lived about 103 million years ago during the late Early Cretaceous period. The specimen is the first ceratopsian dinosaur from the Korean peninsula. The partial skeleton includes a significant portion of the animal's backbone, hip bone, partial hind limbs and a nearly complete tail. Results from the analysis of the specimen were published in ...

Penn study on skin formation suggests strategies to fight skin cancer

Penn study on skin formation suggests strategies to fight skin cancer
2010-12-07
PHILADELPHIA - In a study published in the journal Developmental Cell, Sarah Millar PhD, professor of Dermatology and Cell & Developmental Biology at the University of Pennsylvania School of Medicine, and colleagues demonstrate that a pair of enzymes called HDACs are critical to the proper formation of mammalian skin. The findings, Millar says, not only provide information about the molecular processes underlying skin development, they also suggest a potential anticancer strategy. "Inhibition of these HDAC enzymes might be able to shut down the growth of tumors that ...

Bacteria seek to topple the egg as top flu vaccine tool

2010-12-07
Only the fragile chicken egg stands between Americans and a flu pandemic that would claim tens of thousands more lives than are usually lost to the flu each year. Vaccine production hinges on the availability of hundreds of millions of eggs – and even with the vaccine, flu still claims somewhere around 36,000 lives in the United States during a typical year. Now scientists have taken an important step toward ending the dominance of the oval. In a paper published in the Dec. 6 issue of the journal Vaccine, scientists showed that an experimental flu vaccine grown entirely ...

NIH scientists identify mechanism responsible for spreading biofilm infections

2010-12-07
What: Scientists from the National Institutes of Health have discovered how catheter-related bacterial infection develops and disseminates to become a potentially life-threatening condition. The study, which included research on Staphylococcus epidermidis in mice implanted with catheters, could have important implications for understanding many types of bacterial biofilm infections, including those caused by methicillin-resistant S. aureus (MRSA). Biofilms are clusters of microbes that almost always are found with healthcare-associated infections (HAIs) involving medical ...

LAST 30 PRESS RELEASES:

Scientists unlock secrets behind flowering of the king of fruits

Texas A&M researchers illuminate the mysteries of icy ocean worlds

Prosthetic material could help reduce infections from intravenous catheters

Can the heart heal itself? New study says it can

Microscopic discovery in cancer cells could have a big impact

Rice researchers take ‘significant leap forward’ with quantum simulation of molecular electron transfer

Breakthrough new material brings affordable, sustainable future within grasp

How everyday activities inside your home can generate energy

Inequality weakens local governance and public satisfaction, study finds

Uncovering key molecular factors behind malaria’s deadliest strain

UC Davis researchers help decode the cause of aggressive breast cancer in women of color

Researchers discovered replication hubs for human norovirus

SNU researchers develop the world’s most sensitive flexible strain sensor

Tiny, wireless antennas use light to monitor cellular communication

Neutrality has played a pivotal, but under-examined, role in international relations, new research shows

Study reveals right whales live 130 years — or more

Researchers reveal how human eyelashes promote water drainage

Pollinators most vulnerable to rising global temperatures are flies, study shows

DFG to fund eight new research units

Modern AI systems have achieved Turing's vision, but not exactly how he hoped

Quantum walk computing unlocks new potential in quantum science and technology

Construction materials and household items are a part of a long-term carbon sink called the “technosphere”

First demonstration of quantum teleportation over busy Internet cables

Disparities and gaps in breast cancer screening for women ages 40 to 49

US tobacco 21 policies and potential mortality reductions by state

AI-driven approach reveals hidden hazards of chemical mixtures in rivers

Older age linked to increased complications after breast reconstruction

ESA and NASA satellites deliver first joint picture of Greenland Ice Sheet melting

Early detection model for pancreatic necrosis improves patient outcomes

Poor vascular health accelerates brain ageing

[Press-News.org] Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
Vector-gene combination developed at St. Jude Children's Research Hospital and UCL is central to latest clinical trial of gene therapy as a possible tool to provide long-term relief from disabling bleeds